Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with (89)Zirconium oxine for PET imaging

Mostrar otras versiones (1)

BACKGROUND: Chimeric antigen receptor (CAR) T cell therapy is an exciting cell-based cancer immunotherapy. Unfortunately, CAR-T cell therapy is associated with serious toxicities such as cytokine release syndrome (CRS) and neurotoxicity. The mechanism of these serious adverse events (SAEs) and how h...

Descripción completa

Detalles Bibliográficos
Autores principales: Leland, Pamela, Kumar, Dhiraj, Nimmagadda, Sridhar, Bauer, Steven R., Puri, Raj K., Joshi, Bharat H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246418/
https://www.ncbi.nlm.nih.gov/pubmed/37286997
http://dx.doi.org/10.1186/s12967-023-04142-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246418/
https://www.ncbi.nlm.nih.gov/pubmed/37286997
http://dx.doi.org/10.1186/s12967-023-04142-2

Ejemplares similares